Comparative Pharmacology
Head-to-head clinical analysis: CETIRIZINE HYDROCHLORIDE versus PBZ.
Peer-Reviewed Evidence
Head-to-head clinical analysis: CETIRIZINE HYDROCHLORIDE versus PBZ.
CETIRIZINE HYDROCHLORIDE vs PBZ
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Selective histamine H1-receptor antagonist; inhibits histamine-mediated allergic and inflammatory responses.
PBZ (phenylbutazone) is a nonsteroidal anti-inflammatory drug (NSAID) that inhibits cyclooxygenase (COX) enzymes, reducing prostaglandin synthesis. It also has uricosuric effects.
5-10 mg orally once daily; maximum 10 mg per day.
25-50 mg orally every 4-6 hours as needed; not to exceed 300 mg/day. For severe allergies: 25 mg intramuscularly or intravenously every 4-6 hours.
None Documented
None Documented
Terminal elimination half-life is approximately 8-11 hours in healthy adults; prolonged in renal impairment (up to 20-30 hours in moderate to severe impairment).
Terminal elimination half-life: 8-12 hours in adults; prolonged in renal impairment (up to 24 hours).
Primarily renal (approximately 70% as unchanged drug via glomerular filtration and tubular secretion); minor biliary/fecal elimination (<10%).
Renal excretion of unchanged drug (approximately 70-80%) with the remainder as metabolites. Biliary/fecal excretion accounts for <5%.
Category A/B
Category C
Antihistamine
Antihistamine